- Home
- CTMX vs EBS Comparison
CTMX vs EBS Comparison
Compare CTMX & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTMX | EBS |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 595.6M |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CTMX | EBS |
|---|---|---|
| Price | $5.97 | $10.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $8.86 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 3.7M | 905.5K |
| Earning Date | 03-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.22 | N/A |
| EPS | 0.24 | ★ 1.35 |
| Revenue | $113,631,000.00 | ★ $788,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.21 |
| P/E Ratio | $23.67 | ★ $8.08 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $4.02 |
| 52 Week High | $6.35 | $14.06 |
Technical Indicators
Market Signals| Indicator | CTMX | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 38.27 |
| Support Level | $5.17 | $10.48 |
| Resistance Level | $6.35 | $11.96 |
| Average True Range (ATR) | 0.50 | 0.61 |
| MACD | -0.05 | -0.15 |
| Stochastic Oscillator | 29.01 | 6.19 |
Price Performance
Historical ComparisonAbout CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.